What is the recommended risperidone dose for augmentation of obsessive‑compulsive disorder when added to an SSRI?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Risperidone Augmentation Dosing for OCD

For adults with OCD who have inadequate response to SSRI monotherapy, start risperidone at 0.5 mg daily and titrate gradually to a target dose of 1-3 mg/day, with most patients responding at 2 mg/day or less.

Evidence-Based Dosing Strategy

The most robust evidence comes from multiple controlled trials demonstrating efficacy at relatively low doses:

  • Starting dose: 0.5 mg daily 1, 2
  • Target dose range: 1-3 mg/day 1, 2
  • Typical effective dose: 2-2.3 mg/day (mean in clinical trials) 3
  • Maximum studied dose: 3-4 mg/day 4, 2

Titration Schedule

Begin with 0.5 mg daily and increase gradually over 1-2 weeks based on tolerability. The evidence shows that even very low doses (0.5 mg) can be effective in SSRI-refractory OCD patients 1. Most patients who respond do so at doses ≤2 mg/day, and there is no clear evidence that higher doses provide additional benefit.

Clinical Trial Evidence

A pivotal double-blind RCT found that risperidone augmentation (0.5-3.0 mg/day) produced a 40% response rate versus 0% with placebo in treatment-resistant OCD 2. Another double-blind study demonstrated that 50% of patients responded to risperidone at just 0.5 mg/day when added to fluvoxamine 1.

However, the most important comparative study showed that cognitive-behavioral therapy (EX/RP) was significantly superior to risperidone augmentation (80% response rate for EX/RP vs. 23% for risperidone vs. 15% for placebo) 4. This suggests risperidone should be considered a second-line augmentation strategy when EX/RP is unavailable or not tolerated.

Important Clinical Considerations

Tolerability Profile

Risperidone is generally well-tolerated at these low doses, with the most common side effects being:

  • Mild transient sedation
  • Mild increase in appetite 1
  • Rare mild extrapyramidal symptoms (tremor, akathisia) at doses ≥2 mg 5

Duration of Trial

Allow 8 weeks at therapeutic dose to assess response 2. Response is typically defined as ≥25-35% reduction in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) scores.

Predictors of Response

Better baseline insight into obsessions/compulsions significantly correlates with greater response to risperidone augmentation 2. Patients with comorbid bipolar disorder may show particularly robust responses 5, 6.

Comparative Effectiveness

Recent meta-analytic evidence ranks risperidone among the most effective antipsychotic augmentation agents for OCD, with a standardized mean difference of -0.74 compared to placebo 7. Risperidone demonstrates an optimal balance of efficacy and tolerability compared to other antipsychotics, making it a preferred first-choice augmenting agent when antipsychotic augmentation is indicated 7.

Critical Caveat

Despite these positive findings, EX/RP augmentation should be offered before antipsychotic augmentation given its superior efficacy (effect size approximately 4 times larger than risperidone) and more favorable side effect profile 4, 8.

Practical Algorithm

  1. Confirm adequate SSRI trial (≥12 weeks at therapeutic dose with good adherence)
  2. Offer EX/RP as first-line augmentation if available
  3. If EX/RP unavailable/declined/failed, consider risperidone:
    • Start 0.5 mg daily
    • Increase to 1-2 mg daily over 1-2 weeks
    • Maximum 3 mg daily if no response at lower doses
    • Continue for 8 weeks before declaring treatment failure
  4. Monitor for metabolic side effects and extrapyramidal symptoms
  5. If no response after 8 weeks at 2-3 mg/day, reassess diagnosis and consider alternative strategies

Do not routinely exceed 3 mg/day, as higher doses increase side effect risk without clear evidence of additional benefit in OCD specifically.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.